Comprehensive Safety Testing Shows Exenatide and Saxagliptin Cause No Pancreatic Damage in Animals

This was a comprehensive integration of regulatory toxicology data from more than 70 non-clinical studies conducted under Good Laboratory Practice (GLP) regulations in accordance with ICH and FDA guidelines. Studies included mice, rats, dogs, and non-human primates. Comprehensive pancreas assessments evaluated endocrine and exocrine tissue for any drug-related microscopic changes at multiple time points and dose levels.

This study provides the most definitive preclinical evidence addressing one of the biggest safety concerns ever raised about GLP-1 drugs — the fear that they cause pancreatitis or pancreatic cancer. With over 4,100 pancreata examined at extreme drug exposures, the complete absence of adverse findings provides powerful reassurance. This data was instrumental in regulatory agencies concluding that GLP-1 drugs do not pose a significant pancreatic risk.

The pancreatitis and pancreatic cancer scare nearly derailed the GLP-1 drug class in its early years. This comprehensive safety evaluation, combined with subsequent large-scale human clinical data, has essentially settled the debate. The result has been continued expansion of GLP-1 drug approvals and prescribing, now extending well beyond diabetes to obesity, cardiovascular disease, and emerging neurological indications. This study played a key role in building the safety confidence that enabled that expansion.

This is an industry-sponsored study from the manufacturer of exenatide and saxagliptin, which could introduce bias. Animal toxicology, even across multiple species, cannot perfectly predict human responses. The studies assessed histological endpoints — subclinical functional changes may not have been captured. Chronic low-grade inflammation without visible microscopic changes is theoretically possible. The 2-year maximum duration in rodents may not capture very long-term effects relevant to lifelong human use.